vTv Therapeutics (VTVT) EBITDA Yield: History & Chart

vTv Therapeutics Inc.(VTVT)

Biotechnology · High Point, NC

$30.23-0.10 (-0.35%)

Delayed quote: Oct 6, 2026, 3:50 PM EDT

About vTv Therapeutics Inc.

vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.

High Point, NC

26 employees

www.vtvtherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Paul J. Sekhri

View full financials

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
vTv Therapeutics Inc. (VTVT)	$79.11M	N/A	N/A	N/A	N/A
Acrivon Therapeutics, Inc. Common Stock (ACRV)vs ›	$79.40M	N/A	N/A	N/A	N/A
Citius Oncology, Inc. (CTOR)vs ›	$78.57M	N/A	N/A	N/A	N/A
Inovio Pharmaceuticals, Inc. (INO)vs ›	$77.73M	N/A	N/A	N/A	N/A
Sera Prognostics, Inc. (SERA)vs ›	$77.72M	N/A	N/A	N/A	N/A
Humacyte, Inc. (HUMA)vs ›	$80.79M	N/A	N/A	N/A	N/A
Outset Medical, Inc. (OM)vs ›	$76.75M	N/A	N/A	N/A	N/A
Nutriband Inc. (NTRB)vs ›	$81.63M	N/A	N/A	N/A	N/A
ProMIS Neurosciences, Inc. (PMN)vs ›	$81.79M	N/A	8.07%	4.72%	4.72%
Neonc Technologies Holdings, Inc. (NTHI)vs ›	$75.98M	N/A	N/A	N/A	N/A

NAME

MARKET CAP

EBITDA YIELD

TTM

vTv Therapeutics Inc. (VTVT)

$79.11M

N/A

Acrivon Therapeutics, Inc. Common Stock (ACRV)vs ›

$79.40M

N/A

Citius Oncology, Inc. (CTOR)vs ›

$78.57M

N/A

Inovio Pharmaceuticals, Inc. (INO)vs ›

$77.73M

N/A

Sera Prognostics, Inc. (SERA)vs ›

$77.72M

N/A

Humacyte, Inc. (HUMA)vs ›

$80.79M

N/A

Outset Medical, Inc. (OM)vs ›

$76.75M

N/A

Nutriband Inc. (NTRB)vs ›

$81.63M

N/A

ProMIS Neurosciences, Inc. (PMN)vs ›

$81.79M

N/A

8.07%

4.72%

Neonc Technologies Holdings, Inc. (NTHI)vs ›

$75.98M

N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

EBITDA Yield: N/A

VTVT EBITDA Yield Metrics

VTVT Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics